GALT vs MDGL
GALT: A clinical-stage biopharmaceutical company developing novel carbohydrate-based galectin-3 inhibitors to address advanced liver fibrosis and MASH cirrhosis. MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
Side-by-side fundamentals
| Metric | GALT | MDGL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.64 | $476.91 | |
| Market cap | $240M | $11.0B | |
| Net margin FY2025, SEC XBRL | n/a | -30.1% | |
| Operating margin FY2025, SEC XBRL | n/a | -31.3% | |
| ROE FY2025, SEC XBRL | n/a | -47.8% | |
| ROA FY2025, SEC XBRL | -157.9% | -22.9% | MDGL higher |
| Debt / equity as of 2026-09-03 | 11.09 | 0.65 | MDGL lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +149.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.60 | 0.63 | |
| 1-year return as of 2026-10-08 close | -23.2% | +9.1% | MDGL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.